The target blood pressure in patients with diabetes is <130 mm Hg

Size: px
Start display at page:

Download "The target blood pressure in patients with diabetes is <130 mm Hg"

Transcription

1 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Pro Lars Rydén Karolinska Institutet Stockholm, Sweden

2 Diabetes Lars Rydén and the Heart Karolinska Institutet Stockholm Meet the experts Sweden Disclosures August Research grants The Swedish Heart Lung Foundation The Swedish Medical Research Council AFA Insurance Queen Victoria's and King Gustav V Research Fund Karolinska Institutet Stockholm County Council Sanofi-aventis Astrazeneca Hoffman-LaRoche Honoraria for advisory boards, steering committees, lectures DSMB positions (RELY-ABLE; RED-HF) Exec Steering Committees (ACE; ORIGIN; ALECARDIO; REWIND) Lectures by various Swedish organizations Lectures by various commercial companies

3 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment Conclusion

4 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations

5 Guideline recommendations Variable Treatment target (Chobanian et al JAMA 2003; 289: 2560)

6 Guideline recommendations Variable Treatment target (Graham et al Eur Heart J 2007; 28: 2375)

7 Guideline recommendations Variable Treatment target (Mancia et al Eur Heart J 2007; 28: 1462)

8 Guideline recommendations Variable Lifestyle modification Smoking cessation BP Treatment target Structured education Obligatory <130 / 80 mm Hg Renal dysf <125/75 HbA1c (DCCT standard) 6.5% mmol/l mg/dl Venous plasma glucose < Cholesterol < LDL < HDL male >1.0; female >1.2 40; 76 Triglycerides < (Rydén, Standl et al Eur Heart J 2007; 28: 88)

9 Guideline recommendations Variable Treatment target American Diabetes Association B C Supporting evidence from well-conducted cohort studies Supporting evidence from poorly controlled or uncontrolled trials Conflicting evidence with the weight of evidence supporting the recommendation (ADA Diabetes Care; 34: Suppl 1 January 2011)

10 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information

11 Epidemiological considerations Hypertension and diabetes co-exist too often to be a play of chance Hypertension in patients with diabetes 70 90% Diabetes in patients with hypertension 20 50% (Rydén et al Blood Pressure 2008; 17: 250)

12 Epidemiological considerations Hypertension and diabetes co-exist too often to be a play of chance People with either hypertension or type 2 diabetes are at an increased risk for premature cardiovascular morbidity/mortality The presence of both conditions increases this risk 2 4 times Blood pressure and hyperglycemia are continuous variables (Rydén et al Blood Pressure 2008; 17: 250)

13 Hypertension, Diabetes and Cardiovascular Risk About Diabetes and Cardiovascular Risk 10-year CHD mortality/ person years Rate 250 All patients RR= Patients with diabetes RR=3.2 RR=2.8 RR= RR=4.4 RR=3.4 0 < >200 Systolic blood pressure (mm Hg) (Stamler et al. Diabetes Care. 1993;16:434)

14 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement

15 Myocardial involvement in diabetes Possible interactions with high blood pressure Structural abnormalities Myocyte hypertrophy Deposition of PAS-positive glycoproteins Interstitial edema Extracellular matrix accumulation Myocyte loss and interstitial fibrosis Intramyocardial microangiopathy Not specific for patients with diabetes (Shehadeh & Regan Clin Card 1995; 18:301; Hardin Cor Artery Disease 1996; 7:99)

16 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study American Indians n= Without diabetes or hypertension With diabetes only 642 With hypertension only 614 With diabetes and hypertension 874 Method Echocardiography (Bella et al Am J Card 2001:87;1260)

17 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study % Proportion with left ventricular hypertrophy Gender specific criteria LV mass/height (g/m 2 ) No HTN or DM DM HTN HTN and DM (Bella et al Am J Card 2001:87;1260)

18 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study % 16 Proportion with subnormal left ventricular function Stress corrected LV midwall shortening (%) No HTN or DM DM HTN HTN and DM (Bella et al Am J Card 2001:87;1260)

19 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study Conclusions Diabetes associated with increased LV mass independent of and additive to hypertension related to impaired LV systolic function independent of age, gender, BMI and heart rate Insulin resistance a possible common link (Bella et al Am J Card 2001:87;1260)

20 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment

21 Antihypertensive treatment in patients with diabetes Overview of different drugs Conclusions These overviews showed that the effect on major cardiovascular events of BP-lowering regimens studied were broadly comparable for patients with and without diabetes (Arch Intern Med 2005:165;1410)

22 Antihypertensive treatment in patients with diabetes Systolic Hypertension in the Elderly Program (SHEP) Patients without & 583 with type 2 diabetes Randomised treatment Chlortalidone + atenolol/reserpine Placebo & any prescription Follow up 5 years Mortality, stroke & MI Trial design (Curb et al JAMA 1996; 276: 1886)

23 Events no Antihypertensive treatment in patients with diabetes Systolic Hypertension in the Elderly Program (SHEP) Major cardiovascular events during follow up Active Placebo (Curb et al JAMA 1996; 276: 1886) Diabetes No diabetes Saved/

24 Antihypertensive treatment in patients with diabetes Hypertension Optimal Treatment (HOT) Patients without & with type 2 diabetes Treatment Felodipine + ACE-inhib or betablocker Target diastolic pressure 80; 85; 90 Follow up 3.8 years ( ) Trial design (Hansson et al Lancet 1998; 351:1755I)

25 Event rate/ 1000 patient years Antihypertensive treatment in patients with diabetes Hypertension Optimal Treatment (HOT) Nonfatal/fatal MI and stroke & all CV events All patients Patients with diabetes -51% <90 Diastolic blood pressure (mm Hg) (Hansson et al Lancet 1998; 351:1755I)

26 Antihypertensive treatment in patients with diabetes UKPDS Trial design Patients with type 2 diabetes and hypertension Randomised treatment Tight BP control (758) - mean 144/82 Less tight BP control (390) - mean 154/87 Follow up 8.4 years Diabetes related fatal and non-fatal events (UKPDS 38 Brit Med J 1998; 317: 703)

27 Antihypertensive treatment in patients with diabetes UKPDS Proportion with any fatal or non-fatal diabetes related end-point Proportion dying of diabetes related causes RR 24%; p= RR 32%; p=0.019 (UKPDS 38 Brit Med J 1998; 317: 703)

28 Antihypertensive treatment in patients with diabetes UKPDS Association between systolic blood pressure and macro- and microvascular complications of type 2 diabetes Lowest risk with systolic BP 120 mm Hg No indication of a threshold (Adler et al Brit Med J 2000; 321: 412)

29 Antihypertensive treatment in patients with diabetes ADVANCE Patients with type 2 diabetes Randomised treatment in addition to ongoing therapy Perindopril + Indapamide Placebo Trial design Follow up 4.3 years Composite major macro- and microvascular events (Patel et al Lancet 2007; 370: 829)

30 Antihypertensive treatment in patients with diabetes ADVANCE Impact on blood pressure To be noted 5.6 mm Hg (95%CI ) Entry BP (mm Hg) Mean 145/81 Syst <140 47% Diast <90 41% 2.2 mm Hg (95%CI ) (Patel et al Lancet 2007; 370: 829)

31 Cumulative mortality (%) Antihypertensive treatment in patients with diabetes ADVANCE Impact of study drug on all cause mortality HR 0.86 (95%CI ); p=0.025 Follow up (months) (Patel et al Lancet 2007; 370: 829)

32 Antihypertensive treatment in patients with diabetes ACCORD Trial design Patients with type 2 diabetes Randomised treatment in addition to ongoing therapy Intensive syst BP <120 mm Hg Standard syst BP <140 mm Hg Follow up 4.7 years Composite CV death or non-fatal MI or stroke (ACCORD Study group New Engl J Med 2010; 362: 1575)

33 Antihypertensive treatment in patients with diabetes ACCORD Blood pressure control (ACCORD Study group New Engl J Med 2010; 362: 1575)

34 Antihypertensive treatment in patients with diabetes ACCORD Outcome Primary outcome Nonfatal stroke Side effects % Intensive group 3.3 Standard group 1.3 Nonfatal Myocardial Infarction Cardiovascular death Caveats Low event rate No adjudication Open label design Treatment ad hoc (ACCORD Study group New Engl J Med 2010; 362: 1575)

35 Blood pressure targets by guidelines and CV events Experiences from ONTARGET Trial design Patients with CVD or diabetes with end organ damage Randomised treatment in addition to ongoing therapy Telmisartan 80 mg Ramipril 10 mg Combination of the two Follow up 4.6 years Mortality, CV events and hospitalisation for CHF) (Mancia Rydén et al Circulation 2011; In press)

36 (%) (%) Blood pressure targets by guidelines and CV events Experiences from ONTARGET Baseline SBP 130 mmhg by proportion of visits with BP <130/80 mmhg Proportion of visits BP <130/80 mmhg < 25% 0 8 Death, MI, Stroke or CHF (hosp) Death, MI or Stroke CV death 25 to < 50% 50 to < 75% 4 75% 0 MI CHF (hosp) Stroke (Mancia Rydén et al Circulation 2011; In press)

37 The target blood presssure in patients with diabetes is <130 mm Hg Guideline recommendations On the background to these recommendations Epidemiological information Myocardial involvement Blood pressure lowering treatment Conclusion

38 The target blood presssure in patients with diabetes is <130 mm Hg Concluding remarks on blood pressure management in patients with diabetes Check blood pressure regularly Grand conclusion Treat intensively TRUST Combine several drugs THE GUIDELINES Target <130/80 mm Hg and use common sense Individualise the approach

39 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Rebuttal Lars Rydén Karolinska Institutet Stockholm, Sweden

40 Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart Patients from all day practice 110 centers in 25 countries n= Coronary artery disease with or without diabetes Evidence based medicine The combined use of β-blockade, RAA-inhibition, antiplatelets and statins if not contraindicated One year follow up by management (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)

41 Cumulative survival Multifactorial Intervention in type 2 Diabetes Euro Heart Survey Diabetes and the Heart Impact of Evidence Based Medicine (EBM) on 1-year mortality 1,00 0,99 0,98 0,97 0,96 0,95 0,94 0,93 0,92 0, Time of follow up (days) No DM EBM + No DM EBM - DM EBM + DM EBM - (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)

42 Multifactorial Intervention in type 2 Diabetes The Steno 2 study Outcome total mortality after 13 years Cumulative incidence of death (%) Numbers at risk Conventional Intensive 70 Number 60 Log-rank of P=0.015 patients needed to treat for 13 years to avoid one Death 5 Cardiovascular death 8 Major cardiovascular event 3 Progression to nephropathy Years of follow-up (Gaede et al New Engl J Med 2008; 358: 580 ) Conventional Intensive

43 Multifactorial Intervention in type 2 Diabetes Actual contribution of individual risk factors in improving the UKPDS score in STENO 2 intensive arm HbA1c 13% Lipids 73% Total cholesterol 48% SBP 11% HDL cholesterol 25% Smoking 3% (Gaede et al Diabetes 2004; 53: S39)

44 Patient management in Clinical Practice Euro Heart Survey Diabetes and the Heart Elective consultation (58%) Diabetes 860 (30%) No diabetes (70%) (Anselmino et al Europ J Cardiovasc Prev Rehab 2007;14:28)

45 Patient management in Clinical Practice Euro Heart Survey Diabetes and the Heart Variable Target Outside Target Outside n = pat no % 2007 % Blood lipids (mmol/l) n=589 Cholesterol < n=532 LDL < n=559 HDL > n=585triglycerides < Blood pressure (mm Hg) n=746 <140/90 27 FP-glucose (mmol/l) n=573 < HbA1c (%) n=397 < (Anselmino et al Europ J Cardiovasc Prev Rehab 2008;15:216)

46 Euro Heart Survey Diabetes and the Heart Variable Target Outside Target Outside n = pat no % 2007 % Blood lipids (mmol/l) n=589 Cholesterol < < n=532 LDL < n=559 HDL A considerable > > n=585triglycerides < Blood pressure (mm (mm Hg) Hg) n=746 <140/90 27 <130/80 56 FP-glucose (mmol/l) n=573 < < HbA1c (%) Patient management in Clinical Practice improvement potential n=397 < < (Anselmino and Rydén. Data on file)

47 Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is <130 mm Hg Thanks for the attention!!!

48 Diabetes mellitus and hypertension Effects on left ventricular structure and function The STRONG Heart Study Parameter Population No DM/HT DM HT DM+HT American indians n= Age (years) No diabetes or hypertension Females (%) Diabetes only BMI Hypertension (kg/m 2 ) only BPsyst Diabetes (mmhg) and Hypertension BPdiast Method (mmhg) BP Echocardiography therapy (%) (Bella et al Am J Card 2001:87;1260)

49 Antihypertensive treatment in patients with diabetes UKPDS Proportion of patients requiring 0, 1, 2 or 3 blood pressure lowering drugs during follow up (UKPDS 38 Brit Med J 1998; 317: 703)

50 Antihypertensive treatment in patients with diabetes UKPDS Long term follow up after tight BP control Mean BP for patients assigned to tight or less tight control 10 years from the end of the study 1997 Hazard Ratios for any diabetes related end-point 10 years from the end of study 1997 (Holman et al New Engl J Med 2008; 359: 1565)

Treatment to reduce cardiovascular risk: multifactorial management

Treatment to reduce cardiovascular risk: multifactorial management Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University

More information

Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April

Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April Master class in preventive cardiology Focus on diabetes and cardiovascular disease Geneva April 14 2011 Introduction Course objectives A review of available guidelines Lars Rydén Cardiology Unit Department

More information

Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April

Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

Treating Hypertension in Individuals with Diabetes

Treating Hypertension in Individuals with Diabetes Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Update on CVD and Microvascular Complications in T2D

Update on CVD and Microvascular Complications in T2D Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine

More information

Diabetes and Heart Failure

Diabetes and Heart Failure Diabetes and Heart Failure A common and fatal combination A Aspects on epidemiology, prognosis diagnosis and therapy Lars Rydén Department of Medicine Karolinska Institutet Stockholm, Sweden Diabetes and

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

How to Reduce CVD Complications in Diabetes?

How to Reduce CVD Complications in Diabetes? How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year

More information

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?

Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:

More information

Glycemic control a matter of life and death

Glycemic control a matter of life and death Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

Diabete: terapia nei pazienti a rischio cardiovascolare

Diabete: terapia nei pazienti a rischio cardiovascolare Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population

More information

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria 1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Diabetes and Hypertension

Diabetes and Hypertension Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Preventive Cardiology Scientific evidence

Preventive Cardiology Scientific evidence Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular

More information

Review. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction

Review. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular

More information

The Burden of the Diabetic Heart

The Burden of the Diabetic Heart The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than

More information

A Fork in the Road: Navigating Through New Terrain

A Fork in the Road: Navigating Through New Terrain A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes

More information

Master Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden

Master Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden Master Class in Preventive Cardiology The New MI Phenotype OR Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden The New MI Phenotype OR Coronary disease and glucose abnormalities Klas

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Diabetes Mellitus: Implications of New Clinical Trials and New Medications Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October

More information

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee

More information

American Academy of Insurance Medicine

American Academy of Insurance Medicine American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker

More information

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University

More information

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Is there a mechanism of interaction between hypertension and dyslipidaemia? Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational

More information

T2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets

T2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

ACCORD, ADVANCE & VADT. Now what do I do in my practice?

ACCORD, ADVANCE & VADT. Now what do I do in my practice? ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com

More information

Diabetes new challenges, new agents, new order

Diabetes new challenges, new agents, new order Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating

More information

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977

More information

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Prevention of Stroke Evidence Tables Diabetes Management CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Diabetes Management Coutts S, Wein T (Writing Group Chairs) on Behalf of the PREVENTION of STROKE Writing Group 2014 Heart and Stroke Foundation November 2014

More information

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the

More information

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,

More information

Cardiovascular Management of a Patient with Diabetes

Cardiovascular Management of a Patient with Diabetes Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and

More information

Blood Pressure Treatment Goals

Blood Pressure Treatment Goals Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?

Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

Treating Hypertension in 2018: What Makes the Most Sense Today?

Treating Hypertension in 2018: What Makes the Most Sense Today? Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or

More information

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial 1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

More information

Management of cardiovascular disease. Acute coronary syndromes and intensive care. Lars Rydén Karolinska Institutet Stockholm, Sweden

Management of cardiovascular disease. Acute coronary syndromes and intensive care. Lars Rydén Karolinska Institutet Stockholm, Sweden Management of cardiovascular disease Acute coronary syndromes and intensive care Lars Rydén Karolinska Institutet Stockholm, Sweden Hyperglycemia and acute coronary syndromes Changing fenotype GAMI Study

More information

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS

HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST

More information

Identification of subjects at high risk for cardiovascular disease

Identification of subjects at high risk for cardiovascular disease Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet

More information

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now

Slide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for

More information

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic 1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua

Practical Diabetes. Nic Crook. (and don t use so many charts) Kuirau Specialists 1239 Ranolf Street Rotorua. Rotorua Hospital Private Bag 3023 Rotorua Practical Diabetes (and don t use so many charts) Nic Crook Rotorua Hospital Private Bag 3023 Rotorua Kuirau Specialists 1239 Ranolf Street Rotorua Worldwide rates of diabetes mellitus: predictions 80

More information

Safety of Anacetrapib in Patients with or

Safety of Anacetrapib in Patients with or Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO

More information

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline

More information

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care

Hypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale

Dysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and

More information

Should I use statins?

Should I use statins? I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus

Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus 1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management

More information

Hypertension and the SPRINT Trial: Is Lower Better

Hypertension and the SPRINT Trial: Is Lower Better Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial

Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators

More information

Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial

Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial Medication Adherence and Outcomes in High Risk Cardiovascular Patients in the ONTARGET Trial M. Böhm, H. Schumacher, U. Laufs, P. Sleight, R. Schmieder, T. Unger, K. Koon, S. Yusuf on behalf of the ONTARGET-Investigators

More information

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division

More information

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Update Clinical Controversies Regarding Age and Race Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT

More information

Hypertension Update 2009

Hypertension Update 2009 Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin

More information

Macrovascular Disease in Diabetes

Macrovascular Disease in Diabetes Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based

More information

Cardiovascular disease - from management to prevention

Cardiovascular disease - from management to prevention Cardiovascular disease - from management to prevention Reflections originating from the Fourth Joint European Societies Task Force on Cardiovascular Disease Prevention in Clinical Practice 2007 WHAT IS

More information

Predicting and changing the future for people with CKD

Predicting and changing the future for people with CKD Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University

More information

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain) Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension

More information

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.

Managing Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park. Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information